From 948828b47801e02bc004360f7c65bdd594a266f2 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 14:48:15 +0000 Subject: [PATCH 1/2] extract: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 ++++ ...-cardiovascular-and-metabolic-endpoints.md | 6 ++++ ...eating-largest-per-patient-cost-savings.md | 6 ++++ ...st-effectiveness-analysis-obesity-cvd.json | 32 +++++++++++++++++++ ...cost-effectiveness-analysis-obesity-cvd.md | 15 ++++++++- 5 files changed, 64 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index ff0765e3..ef8b6ecc 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics. + +### Additional Evidence (challenge) +*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* + +At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index b3b29624..e79df92b 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -48,6 +48,12 @@ Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatit FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. The cardiovascular benefits emerged as secondary endpoints in a study designed for kidney outcomes, supporting the multi-organ protection thesis. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors. + +### Additional Evidence (extend) +*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* + +Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 9a39f010..89791f9d 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -34,6 +34,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR decline slowed by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early at prespecified interim analysis due to efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM. + +### Additional Evidence (confirm) +*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16* + +SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.json b/inbox/archive/.extraction-debug/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.json new file mode 100644 index 00000000..72d4d059 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-depends-entirely-on-net-price-with-rebates-shifting-icer-from-136k-to-32k-per-qaly.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-making-metabolic-disease-prevention-the-primary-economic-lever.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-depends-entirely-on-net-price-with-rebates-shifting-icer-from-136k-to-32k-per-qaly.md:set_created:2026-03-16", + "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-making-metabolic-disease-prevention-the-primary-economic-lever.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-cost-effectiveness-depends-entirely-on-net-price-with-rebates-shifting-icer-from-136k-to-32k-per-qaly.md:missing_attribution_extractor", + "glp-1-diabetes-prevention-savings-exceed-cardiovascular-savings-by-10x-making-metabolic-disease-prevention-the-primary-economic-lever.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md b/inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md index 73cfb598..7a5fb4ca 100644 --- a/inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md +++ b/inbox/archive/2025-01-01-select-cost-effectiveness-analysis-obesity-cvd.md @@ -7,9 +7,13 @@ date: 2025-01-01 domain: health secondary_domains: [internet-finance] format: paper -status: unprocessed +status: enrichment priority: medium tags: [glp-1, semaglutide, cost-effectiveness, cardiovascular, SELECT-trial, QALY] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -43,3 +47,12 @@ Cost-effectiveness analysis of semaglutide 2.4mg based on SELECT trial data, mod PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Cost-effectiveness is price-dependent — the declining price trajectory may flip GLP-1s from inflationary to cost-effective faster than the existing claim anticipates EXTRACTION HINT: Focus on the price sensitivity of the cost-effectiveness conclusion and how recent price deals change the math + + +## Key Facts +- SELECT trial modeled lifetime outcomes for obese/overweight patients with established CVD but without diabetes +- Per 100,000 subjects treated (lifetime horizon): 2,791 non-fatal MIs avoided, 3,000 revascularizations avoided, 487 strokes avoided, 115 CV deaths avoided +- Average per-subject lifetime treatment cost: $47,353 +- Australian analysis at A$4,175/year yields ICER of A$96,055/QALY, not cost-effective at A$50,000 threshold +- ICER 2025 assessment: semaglutide would need 80% price reduction to meet standard threshold at list price +- Study was industry-funded by Novo Nordisk From 766ea415fbc516c356d8afb7b9b61913f82be5c7 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 14:52:10 +0000 Subject: [PATCH 2/2] auto-fix: strip 5 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...del makes the net cost impact inflationary through 2035.md | 4 ++-- ...ue-across-kidney-cardiovascular-and-metabolic-endpoints.md | 4 ++-- ...lays-dialysis-creating-largest-per-patient-cost-savings.md | 2 +- 3 files changed, 5 insertions(+), 5 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index ef8b6ecc..8958d793 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -37,13 +37,13 @@ MA plans' near-universal prior authorization creates administrative friction tha ### Additional Evidence (extend) -*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16* +*Source: 2025-05-01-nejm-semaglutide-mash-phase3-liver | Added: 2026-03-16* MASH/NASH is projected to become the leading cause of liver transplantation. GLP-1s now demonstrate efficacy across three major organ systems (cardiovascular, renal, hepatic), which strengthens the multi-indication economic case for chronic use. The 62.9% MASH resolution rate suggests GLP-1s could prevent progression to late-stage liver disease and transplantation, though the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades and falls outside typical budget scoring windows. ### Additional Evidence (extend) -*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16* +*Source: 2025-12-23-cms-balance-model-glp1-obesity-coverage | Added: 2026-03-16* The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics. diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index e79df92b..764c971a 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -38,13 +38,13 @@ SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semagluti ### Additional Evidence (extend) -*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16* +*Source: 2025-05-01-nejm-semaglutide-mash-phase3-liver | Added: 2026-03-16* Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo. Meta-analysis confirms GLP-1 RAs significantly increase histologic resolution of MASH, decrease liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation. Some hepatoprotective benefits appear at least partly independent of weight loss, suggesting direct liver effects beyond metabolic improvement. This adds hepatic protection as a third major organ system (alongside cardiovascular and renal) where GLP-1s demonstrate protective effects. ### Additional Evidence (confirm) -*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* +*Source: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes | Added: 2026-03-16* FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. The cardiovascular benefits emerged as secondary endpoints in a study designed for kidney outcomes, supporting the multi-organ protection thesis. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors. diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 89791f9d..278f2b9b 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -30,7 +30,7 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, ### Additional Evidence (confirm) -*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16* +*Source: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes | Added: 2026-03-16* FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR decline slowed by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early at prespecified interim analysis due to efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM.